Document is current
Any future updates will be listed below
-
Authors
Otero, Claire E. https://orcid.org/0000-0001-7127-2327
Slein, Matthew D. https://orcid.org/0000-0001-8288-787X
Mitchell, Libby https://orcid.org/0009-0003-1189-1873
Ramloul, Adarsh https://orcid.org/0009-0005-3057-2362
Kolb, Philipp https://orcid.org/0000-0001-7935-217X
Ackerman, Margaret E. https://orcid.org/0000-0002-4253-3476
Permar, Sallie R. https://orcid.org/0000-0003-1438-4554
- License Information
-
More Information
Article History
Accepted: 19 February 2026
First Online: 13 March 2026
Competing interests
: S.R.P. has served as a consultant to Moderna, Pfizer, Dynavax, Kamada, Imunon and Merck, and has led sponsored programmes with Moderna, Pfizer, Dynavax and Kamada. M.E.A. has a sponsored project with Moderna and patents/applications related to antibody-based interventions against neonatal herpes simplex virus (nHSV) infection. P.K. serves as a consultant to Oak Hill Bio and had a sponsored project with Biotest AG (2022–2024). These activities had no impact on this article. The other authors declare no competing interests.
